Exchange: NASDAQ·Updated 06:15 PM EDT

LQDA News

News
all
press releases
Liquidia Corporation's (LQDA) Yutrepia Launch Continues to Outpace the Expectations
Liquidia Corporation's (LQDA) Yutrepia Launch Continues to Outpace the Expectations...
Yahoo! Finance: News
More News
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Zacks
Is the Options Market Predicting a Spike in Liquidia Stock?
Investors need to pay close attention to LQDA stock based on the movements in the options market lately.
Zacks
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Zacks
Will LQDA's Differentiated PAH Approach Drive Growth?
LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
Zacks
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
Zacks
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
Zacks
Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited
Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited...
Yahoo! Finance: News
Why Liquidia Stock Was Diving This Week
Key PointsThe shares had risen by 155% year-to-date prior to earnings...
Nasdaq News: Markets
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
Zacks

Advertisement|Remove ads.